King's College London

Research portal

Increased atrial effectiveness of flecainide conferred by altered biophysical properties of sodium channels

Research output: Contribution to journalArticlepeer-review

Sian O' Brien, Andrew P. Holmes, Daniel M. Johnson, S. Nashitha Kabir, Christopher O' Shea, Molly O' Reilly, Adelisa Avezzu, Jasmeet S. Reyat, Amelia W. Hall, Clara Apicella, Patrick T. Ellinor, Steven Niederer, Nathan R. Tucker, Larissa Fabritz, Paulus Kirchhof, Davor Pavlovic

Original languageEnglish
Pages (from-to)23-35
Number of pages13
JournalJournal of Molecular and Cellular Cardiology
PublishedMay 2022

Bibliographical note

Publisher Copyright: © 2022 Elsevier Ltd

King's Authors


Atrial fibrillation (AF) affects over 1% of the population and is a leading cause of stroke and heart failure in the elderly. A feared side effect of sodium channel blocker therapy, ventricular pro-arrhythmia, appears to be relatively rare in patients with AF. The biophysical reasons for this relative safety of sodium blockers are not known. Our data demonstrates intrinsic differences between atrial and ventricular cardiac voltage-gated sodium currents (INa), leading to reduced maximum upstroke velocity of action potential and slower conduction, in left atria compared to ventricle. Reduced atrial INa is only detected at physiological membrane potentials and is driven by alterations in sodium channel biophysical properties and not by NaV1.5 protein expression. Flecainide displayed greater inhibition of atrial INa, greater reduction of maximum upstroke velocity of action potential, and slowed conduction in atrial cells and tissue. Our work highlights differences in biophysical properties of sodium channels in left atria and ventricles and their response to flecainide. These differences can explain the relative safety of sodium channel blocker therapy in patients with atrial fibrillation.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454